Back

Clinical Efficacy and Safety of Achieving Very Low LDL-C Levels With the PCSK9 Inhibitor Evolocumab in the FOURIER Outcomes Trial

28 August 2017 (14:30 - 14:45)
Organised by:
Congress Presentation Part of: Clinical Trial Update 1 Lipids (Epidemiology and Prevention) ESC Premium Access ESC Congress 2017

About the speaker

Photo
Doctor Robert Giugliano

Brigham and Women's Hospital, Boston (United States of America)

5 More presentations in this session

Presentation thumbnail
Increased all-cause mortality with intensive blood-pressure control in patients with a baseline systolic blood pressure of >=160 mmHg and a Lower Framingham risk score: a cautionary note from SPRINT
Professor T. Wang (Taipei, TW)
Slides Video
Presentation thumbnail
Systolic Blood Pressure Variability and Major Adverse Outcomes in Patients with Atrial Fibrillation: the AFFIRM Study
Associate Professor M. Proietti (Milan, IT)
Slides Video
Presentation thumbnail
The long-term efficacy and safety of short dual antiplatelet therapy
Professor M. Nakamura (Tokyo, JP)
Slides Video
Presentation thumbnail
Mechanisms for the benefit of spironolactone in resistant hypertension in the PATHWAY-2 study
Professor B. Williams (London, GB)
Slides Video
Presentation thumbnail
Aldosterone Lethal Effects Blocked in Acute Myocardial Infarction Treated With or Without Reperfusion to Improve Outcome and Survival at Six Months Follow-up
Professor F. Beygui (Caen, FR)
Slides Video

Access the full session

Session thumbnail
Clinical Trial Update 1

The Event

Event poster

ESC Congress 2017

28 August 2017 14:30 CET
You may be interested in
thumbnail
Congress Presentation
Carotid plaques stabilization and regression with evolocumab
1 September 2025
thumbnail
Congress Presentation
Early PCSK9 inhibitor subscription during episode of acute myocardial infarction (EPISODE-AMI) study
1 September 2025
thumbnail
Webinar
Lipid management pathways and ESC Guidelines
10 January 2023
thumbnail
Congress Presentation
Cardiovascular Efficacy of Evolocumab in Patients with Obesity: Updates from FOURIER Trial
2 September 2024

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources